Type II glycogenosis treatment

摘要

Recombinant human α-Glucosidase (GAA) produced in a Chinese hamster ovary cell culture for use in a method of treating type II glycogenosis in a human being, or in a method of treating cardiomyopathy associated with glycogenosis type II in a human being, where the human being is CRIM-negative for endogenous acid α-glucosidase and where said recombinant human acid α-glucosidase is co-administered with an immunotherapeutic or immunosuppressive regimen.